Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial
Lipids in Health and Disease 201918:31; https://doi.org/10.1186/s12944-019-0967-x
Rohith N. Thota, Shamasunder H. Acharya and Manohar L. Garg
- Off topic: Curcumin reduces diabetes and many other health problems
- Large amounts of curcumin might activate the Vitamin D receptor – Dec 2010
- ALS reduction far more likely if take Curcumin, Luteolin, CBD, Omega-3, or Vitamin D etc – April 2018
- Alzheimer’s may be treated by vitamin D3 and curcumin – March 2012
- Natural Ways to Increase Calcitriol and Activate The Vitamin D Receptor Gene – Oct 2017
- Curcumin extract for prevention of type 2 diabetes July 2018 - includes video summary
"After nine months of treatment, 16 % of subjects in the placebo group went on to get full-blown diabetes. "
:How many in the curcumin group? None."
Overview Diabetes and vitamin D contains the following summary
- Diabetes is 5X more frequent far from the equator
- Children getting 2,000 IU of vitamin D are 8X less likely to get Type 1 diabetes
- Obese people get less sun / Vitamin D - and also vitamin D gets lost in fat
- Sedentary people get less sun / Vitamin D
- Worldwide Diabetes increase has been concurrent with vitamin D decrease and air conditioning
- Elderly get 4X less vitamin D from the same amount of sun
Elderly also spend less time outdoors and have more clothes on
- All items in category Diabetes and Vitamin D
430 items: both Type 1 and Type 2
Vitamin D appears to both prevent and treat diabetes
- Appears that >2,000 IU will Prevent
- Appears that >4,000 IU will Treat , but not cure
- Appears that Calcium and Magnesium are needed for both Prevention and Treatment
which are just some of the vitamin D cofactors
Lowering insulin resistance and dyslipidaemia may not only enhance glycaemic control but also preserve the β-cell function, reducing the overall risk of developing type 2 diabetes (T2D). The current study was aimed to evaluate the effects of curcumin and/or long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) supplementation on glycaemic control and blood lipid levels in individuals at high risk of developing T2D.
This was a 2 × 2 factorial, randomised, double-blinded, placebo-controlled study.
Participants were allocated to either
- double placebo (PL) or
- curcumin plus placebo matching for LCn-3PUFA (CC), or
- LCn-3PUFA plus placebo matching for curcumin (FO), or
- curcumin plus LCn-3PUFA (CC-FO)
for twelve weeks. Primary outcome of the trial was glycaemic indices (HbA1C, fasting glucose and insulin). Insulin resistance and sensitivity is measured using homeostatic model assessment model.
A total of sixty-four participants (PL, n = 16; CC, n = 15; FO, n = 17, CC-FO, n = 16) were included in the final analysis. Post-intervention, HbA1c and fasting glucose remained unchanged across all the groups. Insulin sensitivity was significantly improved in the CC supplemented group (32.7 ± 10.3%) compared to PL (P = 0.009). FO and CC-FO tended to improve insulin sensitivity by 14.6 ± 8.5% and 8.8 ± 7.7% respectively, but the difference did not reach significance. Triglyceride levels were further increased in the PL (26.9 ± 7.4%), however, CC and CC-FO supplementation reduced the triglycerides, FO resulted in the greatest reduction in triglycerides (− 16.4 ± 4.5%, P < 0.001).
Reduction in insulin resistance and triglycerides by curcumin and LCn-3PUFA appears to be attractive strategies for lowering the risk of developing T2D. However, this study failed to demonstrate complimentary benefits of curcumin and LCn-3PUFA on glycaemic control.
Trail registration ACTRN12615000559516.